mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3

Recent clinical trials using rapalogues in tuberous sclerosis complex (TSC) show regression in volume of typically vascularised tumours including angiomyolipomas (AMLs) and sub-ependymal giant cell astrocytomas (SEGAs). By blocking mechanistic/mammalian target of rapamycin complex 1 (mTORC1) signall...

Descripción completa

Detalles Bibliográficos
Autores principales: Dodd, Kayleigh M., Yang, Jian, Shen, Ming Hong, Sampson, Julian R., Tee, Andrew R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4172452/
https://www.ncbi.nlm.nih.gov/pubmed/24931163
http://dx.doi.org/10.1038/onc.2014.164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4172452/
https://www.ncbi.nlm.nih.gov/pubmed/24931163
http://dx.doi.org/10.1038/onc.2014.164

Ejemplares similares